Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices 52053 

To increase awareness of the 

seriousness of diabetes, its risk factors, 

and strategies for preventing diabetes 

and its complications among people at 

risk for diabetes; (2) to improve 

understanding about diabetes and its 

control and to promote better selfmanagement behaviors among people 

with diabetes; (3) to improve health care 

providers’ understanding of diabetes 

and its control and to promote an 

integrated approach to care; (4) to 

promote health care policies that 

improve the quality of and access to 

diabetes care. 

Multiple strategies have been devised 

to address the NDEP objectives. These 

have been described in the NDEP 

Strategic Plan and include: (1) Creating 

partnerships with other organizations 

concerned about diabetes; (2) 

developing and implementing 

awareness and education activities with 

special emphasis on reaching the racial 

and ethnic populations 

disproportionately affected by diabetes; 

(3) identifying, developing, and 

disseminating educational tools and 

resources for the program’s diverse 

audiences; (4) promoting policies and 

activities to improve the quality of and 

access to diabetes care. 

The NDEP evaluation will document 

the extent to which the NDEP program 

has been implemented, and how 

successful it has been in meeting 

program objectives. The evaluation 

relies heavily on data gathered from 

existing national surveys such as 

National Health and Nutrition 

Examination Survey (NHANES), the 

National Health Interview Survey 

(NHIS), the Behavioral Risk Factor 

Surveillance System (BRFSS), among 

others for this information. This generic 

clearance request is for the collection of 

additional primary data from NDEP 

target audiences on some key process 

and impact measures that are necessary 

to effectively evaluate the program. 

Approval is requested for a survey of 

audiences targeted by the National 

Diabetes Education Program including 

people at risk for diabetes, people with 

diabetes and their families and the 

public. 

Frequency of Response: On occasion. 

Affected Public: Individuals or 

households. Type of Respondents: 

Adults. The annual reporting burden is 

as follows: Estimated Number of 

Respondents: 3759, Estimated Number 

of Responses per Respondent: 1; 

Average Burden Hours per Response: 

.153; and Estimated Total Annual 

Burden Hours Requested: 575. There are 

no Capital, Operating or Maintenance 

Costs to report. 

ESTIMATES OF HOUR BURDEN

Type of respondents Number of 

respondents 

Frequency 

of response 

Average 

time per 

response 

Total hour 

burden 

Screening interview with ineligible persons ..................................................................... 1659 1 .03 50 

Eligible respondents ........................................................................................................ 2100 1 .25 525 

Totals ........................................................................................................................ 3759 .................... .................... 575 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Joanne Gallivan, 

M.S., R.D., Director, National Diabetes 

Education Program, NIDDK, NIH, 

Building 31, Room 9A06, 31 Center 

Drive, Bethesda, MD 20892, call the 

non-toll-free number 301–494–6110 or 

e-mail your request, including your 

address to: Joanne_Gallivan@nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Dated: June 9, 2008. 

Elizabeth E. Greene, 

Executive Officer, NIDDK, National Institutes 

of Health. 

Editorial Note: This document was 

received in the Office of the Federal Register 

on September 3, 2008. 

[FR Doc. E8–20636 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; Comment 

Request; Simulations for Drug Related 

Science Education 

SUMMARY: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institute on Drug Abuse (NIDA), the 

National Institutes of Health (NIH) has 

submitted to the Office of Management 

and Budget (OMB) a request for review 

and approval of the information 

collection listed below. This proposed 

information collection was previously 

published in the Federal Register on 

June 26, 2008, (Vol. 73 No. 124, page 

36337) and allowed 60-days for public 

comment. No public comments were 

received. The purpose of this notice is 

to allow an additional 30 days for public 

comment. The National Institutes of 

Health may not conduct or sponsor, and 

the respondent is not required to 

respond to, an information collection 

that has been extended, revised, or 

implemented on or after September 24, 

2008, unless it displays a currently valid 

OMB control number. 

Proposed Collection: Title: 

Simulations for Drug Related Science 

Education. Type of Information 

Collection Request: NEW. Need and Use 

of Information Collection: This is a 

request for a one-time clearance to 

evaluate an interactive multimedia 

module developed by ArchieMD. This 

evaluation seeks to determine whether 

the multimedia module Archie MD: The 

Science of Drugs (1) Increases students’

knowledge in brain and heart biology 

and the effects drugs have on the body 

(2) Increases positive attitudes towards 

science education for high school 

students (3) Reinforce or instill negative 

mstockstill on PROD1PC66 with NOTICES

52054 Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices 

attitudes towards substance abuse. In 

order to test the effectiveness of the 

interactive multimedia module, data 

will be collected in the form of pre and 

post test surveys from 10th and 11th 

grade high school students utilizing the 

developed module. The findings will 

provide valuable information regarding 

information pertaining to the use of 

interactive multimedia educational 

modules in high school science 

classrooms and their ability to increase 

knowledge and change attitudes and 

perceptions. 

Frequency of Response: 4. Affected 

Public: High school students engaged 

with the ArchieMD: The Science of 

Drugs program. Type of Respondent: 

Participants will include high school 

students enrolled in the tenth and 

eleventh grade. Estimated Total Annual 

Number of Respondents: 360. Estimated 

Number of Responses per Respondent: 

4. Average Burden Hours per Response: 

One high school period lasting 50 

minutes. Estimated Total Annual 

Burden Hours Requested: 1199.95. 

There are no Capital Costs to report. 

There are no Operating or Maintenance 

Costs to report. The estimated 

annualized burden is summarized 

below. 

Type of respondents Number of 

respondents 

Frequency 

of response 

Average 

burden hours 

per response 

Estimated total 

burden hours 

requested 

Participants—High School Students ................................................................ 360 4 .8333 1199.95 

Total .......................................................................................................... 360 4 .8333 1199.95 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(2) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (3) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plans, please 

contact Dr. Cathrine Sasek, Coordinator, 

Science Education Program, Office of 

Science Policy and Communications, 

National Institute on Drug Abuse, 6001 

Executive Blvd, Room 5237, Bethesda, 

MD 20892, or call non-toll-free number 

(301) 443–6071; fax (301) 443–6277; or 

by e-mail to csasek@nida.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60-days of the date of 

this publication. 

Dated: August 25, 2008. 

Mary Affeldt, 

Associate Director for Management, National 

Institute on Drug Abuse, National Institutes 

of Health. 

[FR Doc. E8–20778 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of federally 

funded research and development. 

Foreign patent applications are filed on 

selected inventions to extend market 

coverage for companies and may also be 

available for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301–

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Over-Expression and Mutation of a 

Tyrosine Kinase Receptor FGFR4 in 

Tumors 

Description of Technology: 

Rhabdomyosarcoma (RMS) is the most 

common type of pediatric soft tissue 

sarcoma. Most children (>70%) with the 

disease die at higher stage (metastatic 

disease). 

Researchers at NIH have identified 

mutations in fibroblast growth factor 

receptor 4 (FGFR4) that are associated 

with RMS tumors. It is proposed that 

individuals with FGFR4 mutations may 

have an increased risk for tumor 

metastasis. The identified FGFR4 

variants can be used to identify 

individuals who may benefit most from 

treatment with an FGFR4 inhibitor as an 

adjuvant to standard anticancer 

therapeutics to decrease the risk of 

tumor metastasis. 

Available for licensing are methods 

for identifying candidates for treatment 

with an inhibitor of FGFR4 by 

determining the presence of at least one 

FGFR4 variant, kits for identifying said 

candidates, and methods for identifying 

compounds that induce tumor cell 

death or that inhibit tumor growth or 

metastasis. 

Applications: 

• Potential new method for treatment 

of Rhabdomyosarcomas (RMS). 

• Potential new method to prepare 

kits to diagnose activating mutations in 

FGFR4. 

• These mutations can be used in 

laboratory settings to screen thousands 

of compounds for more specific FGFR4 

gene inhibitors. 

• FGFR4 is also a potential target for 

lung and breast cancer. 

• FGFR4 monoclonal can be 

developed to target RMS tumors. 

Market: 

• In the United States, approximately 

12,000 new cases of cancer are 

diagnosed in children each year. 

Childhood cancer remains the leading 

disease-related cause of death in 

children and adolescents in North 

America, with about 2,300 deaths each 

year. 

• Rhabdomyosarcoma accounts for 

about 3 percent of childhood cancers. In 

the U.S., about 350 children are 

diagnosed with Rhabdomyosarcoma 

each year. 

Development Status: Early-stage of 

development. 

Inventors: Javed Khan et al. (NCI). 

mstockstill on PROD1PC66 with NOTICES